e-learning
resources
Barcelona 2013
Tuesday, 10.09.2013
Epidemiological and public health features of tuberculosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Systematic review of shorter 2-3 months regimens for treatment of latent tuberculosis
C. Acuna-Villaorduna, J. Lau-Deza, J. Mora (Scranton, Philadelphia, United States Of America)
Source:
Annual Congress 2013 –Epidemiological and public health features of tuberculosis
Session:
Epidemiological and public health features of tuberculosis
Session type:
Oral Presentation
Number:
3533
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Acuna-Villaorduna, J. Lau-Deza, J. Mora (Scranton, Philadelphia, United States Of America). Systematic review of shorter 2-3 months regimens for treatment of latent tuberculosis. Eur Respir J 2013; 42: Suppl. 57, 3533
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Developing the pneumonia-optimized ratio for community-acquired pneumonia: an easy, inexpensive and accurate prognostic biomarker
Relationship of respiratory disorders of sleep with cognitive impairment and neurological diseases
Evaluating 17 years of latent tuberculosis infection screening in north-west England: a retrospective cohort study of reactivation
Related content which might interest you:
Clinical characteristics and treatment outcomes of patients with pulmonary tuberculosis with delayed conversion over 4 months
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015
A novel nurse-led approach improves treatment completion rates for latent tuberculosis infection (LTBI) treatment
Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches
Year: 2014
Prevalence of inappropriate tuberculosis treatment regimens: a systematic review
Source: Eur Respir J 2012; 39: 1012-1020
Year: 2012
Effectiveness of mandatory treatment for tuberculosis - An observational registry study
Source: Annual Congress 2013 –Epidemiological and public health features of tuberculosis
Year: 2013
Adherence to the recommendation of prescribing 4 drugs in the intensive phase of the standard treatment of tuberculosis in Spain
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3
Year: 2014
Predictors of defaulting from treatment among patients with tuberculosis
Source: International Congress 2015 – Management of TB: a patient focus
Year: 2015
Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Treatment of latent tuberculosis infection with 6 months isoniazid therapy in pediatric population
Source: Eur Respir J 2005; 26: Suppl. 49, 624s
Year: 2005
When do we extend the treatment of tuberculosis (TB) more than 6 months?
Source: Annual Congress 2007 - Clinical tuberculosis
Year: 2007
Restarting biologic agents in rheumatology patients who developed tuberculosis under TNFα-inhibitor treatment
Source: International Congress 2015 – Latent TB infection and screening
Year: 2015
The effectiveness of pulmonary TB treatment in patients with organic liver diseases, depending on the way of administration of anti-TB drugs
Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe
Year: 2016
The risk of tuberculosis in HIV infected in the 12 years of observation
Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment
Year: 2013
Rapid monitoring of tuberculosis treatment response: A multi-centre study
Source: International Congress 2016 – Advances in tuberculosis diagnosis and monitoring of treatment
Year: 2016
Could side effects of MDR-TB treatment change the outcome of the disease?
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015
Liver injury in treatment of latent tuberculosis infection - is the age cut-off for treatment justified?
Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches
Year: 2014
Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion
Source: Eur Respir J 2015; 45: 1170-1173
Year: 2015
Is it necessary to give tuberculosis treatment daily throughout?
Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 1
Year: 2014
Patients over 35 years experience more side-effects during latent TB treatment: Experience from an urban hospital with a high incidence of Tuberculosis
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015
Gene-Xpert for rapid detection of MDR-TB in re-treatment cases;a comparison with standard culture and DST
Source: International Congress 2015 – WHO guidelines in TB and clinical practice
Year: 2015
Prospects for early implementation of ambulatory treatment in XDR TB patients by optimizing the administration of linezolid at the intensive phase of chemotherapy
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept